Challenges to cancer control by screening

Michael N. Pollak and William D. Foulkes

Population-based screening seems to be a common-sense strategy for controlling cancer, but recent reports have raised controversy concerning the benefits of common screening procedures. Intense efforts to develop and evaluate novel screening technologies are underway; however, effective use of any screening method must take into account any underlying biological considerations. What are these biological issues, and what challenges do clinicians face in screening for common cancers?

Screening populations for the presence of an asymptomatic illness will clearly be useful if the screening method is convenient and inexpensive, if false negatives and false positives are rare, and if treatment that was initiated at the early, screening-detected stage is more successful than treatment initiated later in the natural history of the illness. Although it is true that the outcome of cancer treatment is almost always more favourable when treatment is initiated early, it is simplistic to extrapolate that, in general, population screening will provide a practical method for cancer control. Indeed, recent reports have raised controversy concerning the benefits of common screening procedures, such as breast self-examination (see [TIMELINE](#)), mammography and prostate-specific antigen (PSA) measurements^{1–3}.

Important issues include lack of benefit of early detection of disease that cannot be effectively treated and, conversely, early detection of conditions that have a low or unknown

probability of causing clinical disease later in life. Screening procedures must be evaluated not only from the point of view of individuals at risk, but also from the point of view of populations at risk — conclusions obtained from rigorous assessments of screening methods might not always correspond to expectations.

As long as our ability to treat advanced cancer remains inadequate, there will be obvious pressure to implement effective screening strategies, and new technologies for detecting cancer — for example, spiral computed tomography (CT) imaging for lung cancer detection and proteomic serum assays for **ovarian cancer** detection — are being developed at present^{4,5}. However, success of a screening method in detecting cancers before they are clinically apparent is not necessarily sufficient for a screening method to be useful.

Biological issues affect screening. Often, research agendas that are designed to improve cancer screening methods emphasize technology development (for example, serum proteomics or high-definition digital mammography), and assign relatively little attention to the biological characteristics of cancers that influence the efficacy of screening efforts. Yet, the task of developing and implementing effective screening-based methods for cancer control is challenging for biological reasons that deserve consideration.

Stepwise progression to malignancy. The fact that carcinogenesis rarely involves a single transforming step from normal cells to aggressive cancer cells complicates the issue

of screening. A method that identifies only fully transformed neoplastic cells with metastatic potential might indeed result in earlier detection than would be the case if patients were assessed only by clinical examination. However, a significant proportion of such lesions might have already resulted in micrometastases when detected, thereby limiting the benefits of early surgical removal and the entire screening exercise ([FIG. 1](#)). Although many screen-detected cancers have good prognostic features⁶, the fact that a cancer is detected by screening does not guarantee curability.

Screening methods that attempt to avoid this hazard by detecting the presence of cells earlier in the process of stepwise carcinogenesis face different challenges. There is evidence that some partially transformed cells progress very slowly (over decades) towards a clinically aggressive phenotype. Furthermore, carcinogenesis occurs in a parallel manner among at-risk cell lineages. In many organs, early neoplastic lesions are much more common than aggressive cancers. For example, polyps are more frequent than cancers in the **colon**⁷, and there is evidence that approximately 40% of all men over the age of 60 years have prostate neoplasia that is detectable at autopsy, but only 3% have lesions that will affect their lifespan^{8,9}.

PSA measurement is an important example of a sensitive screening method that can detect the presence of neoplastic cells relatively early in the transformation process, compared with most imaging-based screening techniques¹⁰. The rate of neoplastic progression in **prostate cancer**, as in other cancers, varies considerably between tumours. There is evidence that progression of a large subset of prostate neoplastic lesions towards an aggressive phenotype is slow, requiring years or even decades. If PSA or more sensitive screening methods were to allow identification of all men with some form of neoplasia, a situation would arise in which a large proportion of the elderly male population would

Timeline | Breast self-examination — changing attitudes

require intervention. Such screening results would not represent false positives in a technical sense, as neoplasia would, in fact, be present, but the results would be problematic clinically as the natural history of many (but not all) screening-detected lesions would be favourable.

In clinical practice, PSA screening often leads to difficult choices for men who discover the presence of lesions of uncertain prognosis. Clinicians who advise men found to have elevated PSA on screening must first rule out frank false positives (related to prostatitis, for example), usually by biopsy. If neoplasia is confirmed, clinical judgment — taking into account the patient's age, co-morbid conditions and clues regarding prognosis, such as the Gleason score — is needed to decide if intervention is in the patient's best interest. Many patients, understanding that their lesion might or might not result in clinical illness if left untreated, choose to accept treatments with non-trivial morbidity 'just to be sure'. However, this might not provide the anticipated piece of mind, as many treated men experience anxiety concerning risk of recurrence^{11,12}. Although there is a risk that PSA screening might fail to be of value because of highly aggressive interval cancers that can arise between sequential PSA measurements, in practice this is less frequently encountered than the detection of neoplastic lesions that are unlikely to result in clinical illness if left untreated, represented by tumour 3 in FIG. 1.

In contrast to certain screening methods for other cancers in which insufficient sensitivity is a significant limitation, PSA screening represents an example of a screening method in which the main limitation is that only subsets of those identified on screening require intervention. The overall benefit of PSA screening programmes must take into account both the

potentially life-saving benefits of curative early intervention in men with aggressive prostate cancer, and the cost and morbidity of identifying and treating lesions that are not destined to cause significant clinical illness. The discovery of genetic, serum or tumour markers that could be used in conjunction with PSA to allow screening for the presence of the subset of lesions that are likely to lead to clinically important illness could rapidly alter the landscape of prostate cancer screening. Research in this area is ongoing: recent data raises the possibility that serum analytes that are related to insulin growth factor (IGF) physiology might be related specifically to the risk of aggressive prostate cancer^{13,14}.

This research topic is challenging because there is likely to be a strong stochastic component to the fate of individual partially transformed cells — some might accumulate further mutations that will result in malignant progression, whereas others might remain stable or even accumulate mutations that result in apoptotic death. A concept that deserves study is the notion that germline genetic factors — distinct from somatic-cell genetics — might influence the speed of step-wise carcinogenesis, and so offer clues to identifying individuals in whom early lesions are particularly dangerous. Defective DNA repair represents one obvious example in this regard, but more subtle influences involving the effects of hormonal milieu or the probability of survival as compared with apoptosis of at-risk cells also deserve investigation.

These challenges are more complex than conventional concerns of 'false-positive' and 'false-negative' screening tests. Conventional evaluations focus on the ability of a screening test to detect a lesion, with less emphasis on the definition of biological characteristics of lesions that are worth detecting. All would agree that identifying a

cyst as a cancer is a false positive (and one that will be relatively easy to remedy with improved technology), but in a biological sense identifying and targeting for surgery an early cancer that is not destined to ever cause illness is also a false positive.

Heterogeneity. Heterogeneity between cells of a single macroscopic cancer is well documented. Not only is there heterogeneity in the sense of different cell types (such as stromal, vascular and neoplastic) that comprise a tumour, but, more importantly, heterogeneity in gene expression is usually considerable even in analyses that are confined to the frankly neoplastic cells of a lesion¹⁵. A common example for clinicians is the heterogeneity of oestrogen-receptor expression among the individual malignant breast epithelial cells that comprise a **breast cancer**.

This heterogeneity complicates the development of tumour markers because the very notion of expression of a 'marker' by a 'tumour' is a simplification of the biological reality that, during the natural history of a particular neoplasm, the percentage of cells that express a given antigen will vary. Neoplastic progression towards aggressive cancer occurs simultaneously among many clonal populations, which independently undergo somatic-cell mutational events.

Sophisticated proteomic analysis of neoplastic cells obtained from a tumour specimen by laser capture microdissection might minimize concerns related to heterogeneity between neoplastic and stromal cells, but it does not address the problem of heterogeneity within the neoplastic cell population. Data obtained from a single cancer represent an integration of expression information from many individual cells. Gene-expression signatures indicating aggressive neoplastic behaviour are being developed, but, if the proportion of cells with the signature is small, the signal might be obscured by a large majority of sample cells that do not express the signature. So, negative results for a serum marker that is used for screening might indicate an absence of cancer, but also the presence of a cancer at a stage where only a small percentage of the cancer cells express the marker. A special case that might show promise is the use of marker proteins that are necessary for an aggressive phenotype, rather than those that are simply associated with malignancy.

Small lesions can be aggressive. The notion that cancer deaths in a population can be significantly reduced by public-health programmes based on the credo 'find it early and cut it out'

Figure 1 | When in the natural history of a cancer will screening be useful? This varies according to the biological behaviour of the tumour. In the illustration, 'M' indicates the timepoint at which aggressive tumour cells metastasize. In the case of tumour 1, screening and resection at time A will result in cure of an otherwise lethal cancer, whereas screening and resection at time B will not prevent death from metastasis. In the case of tumour 2, screening at time A will represent a technical triumph, as the primary lesion is small and perhaps hard to detect, but will not be helpful, as this cancer has already metastasized. Detection at time B will be of even less value. In the case of tumour 3, the natural history is non-aggressive: successful screening at either time point will probably lead to interventions, possibly with associated risks, for a cancer that would never have caused a clinically important illness.

is simplistic, because the size of the primary lesion is only imperfectly related to metastatic potential. **Small-cell lung cancer** (SCLC) provides an example in which the probability of metastatic dissemination of even very small neoplasms is high. Small breast cancers are less likely than SCLC to metastasize early; however, the probability of metastatic spread before detection of breast cancers by screening is high enough that large numbers of women are offered adjuvant hormonal or chemotherapies following resection of apparently localized lesions. The fact that such adjuvant therapies improve survival represents medical progress, but, conversely, indicates that current screening does not always detect breast cancer early enough. Also problematic is the fact that, at present, no screening method, even accompanied by detailed ancillary investigations of screening-detected lesions, identifies with certainty those breast cancers in which surgical cure can be guaranteed, rendering adjuvant therapy unnecessary. Consequently, many women who are, in fact, surgically cured must undergo adjuvant therapies. Conversely, chemotherapy might not be offered to women with very small breast cancers. These tumours usually have a very good prognosis, but, in

some circumstances, such as in the presence of **BRCA1** mutations, small size and negative nodal status might not guarantee a good prognosis¹⁶. Identifying women who are **BRCA1**-mutation carriers before diagnosis (or at least before treatment) might result in different therapeutic decisions. Recent progress¹⁷ in defining breast cancer gene-expression signatures that are associated with poor prognosis even in the presence of small tumour size represents an important step towards the successful selection of patients for adjuvant treatment. However, this emphasizes one of the challenges to effective screening: certain tumours might be life-threatening even if they are found before they become large.

Varied risk, customized screening? Cancer screening methods might be applied universally according to age and gender, to selected subpopulations or to individuals. There are well-known groups (such as those with genetic predisposition or accidental carcinogen exposure) in which it might make sense to consider screening strategies that are different from those applied in the general population. However, the fact that a subgroup has a higher risk of cancer does not necessarily mean that more intensive screening will result in clinical benefits. Benefits will depend on the ability of the screening method to detect cancers at a curable stage.

This problem is exemplified by women who carry germline **BRCA1** or **BRCA2** mutations. Such women have a particularly high risk of developing breast cancer. The average age of onset of **BRCA1/2**-related breast cancer is also at least 15 years younger than in the general population, so if mammography is going to influence survival in these women, it must be started no later than the fourth, or early in the fifth, decade of life. It might be expected that the positive predictive value of mammography would be higher for women at increased risk than for women at average risk. This might be offset, however, by their younger age of onset — when the breasts are expected to be denser and mammography is less effective at detecting neoplasia — and the generally unfavourable biological characteristics of **BRCA1/2**-related breast cancers¹⁸. The typical **BRCA1** tumour — a high-grade, oestrogen-receptor-negative, **p53**-positive cancer occurring in a young woman — has precisely the characteristics of those tumours that are most likely to be diagnosed in the interval between screening examinations¹⁹, and recent data show that **BRCA1** tumours often present as 'interval cancers'²⁰ and are aggressive¹⁶. Interestingly, in the positive Swedish two-counties mammography trial,

there was no survival benefit for women in the screened arm who developed high-grade invasive ductal carcinomas at 50 years of age or younger²¹. Furthermore, in a retrospective cohort of women who had been diagnosed with breast cancer and had been tested for **BRCA1/2** mutations, mammography performed before surgery was significantly less likely to show a cancer if the woman was a mutation carrier and was either under 50 years of age at diagnosis, had a small tumour, or both²². So even if frequent screening were to be performed, **BRCA1/2**-related breast tumours might be missed by mammography. These findings, when taken together, indicate that accepted techniques, such as mammography, might not significantly reduce breast cancer mortality in **BRCA1/2**-mutation carriers. Other imaging modalities, such as magnetic resonance imaging (MRI), will probably outperform mammography in **BRCA1/2** carriers^{23,24}, but the question of the appropriate screening interval for **BRCA1/2**-mutation carriers remains unanswered, and MRI studies in **BRCA1/2**-mutation carriers have yet to report medium-term follow-up data. Even if these studies show the benefits of MRI, it might not be practical to shorten screening intervals to the extent that is necessary to detect curable cancers — four breast MRIs per year, even if possible, might not be a practical method for breast cancer control in high-risk women. Surgical prevention would probably be more effective than screening²⁵, but it has not been universally accepted by women at risk²⁶. Increasing acceptance of surgical measures might lessen the need for effective screening for **BRCA1/2**-related breast cancer, but it is difficult to imagine that successful surgical intervention will completely obviate the need for better screening tests.

If it is assumed that the general population contains subpopulations that vary in the degree of benefit that screening would provide, the question of reviewing all individuals to identify the subpopulations for which screening should either be emphasized or avoided arises. 'Targeted' screening of selected subpopulations is appealing because the benefits of screening would increase if those who do not benefit — either because they are predisposed to cancers that are so aggressive that screening is unlikely to result in cures, or because they have a very low risk of cancer — were excluded. So far, few studies have addressed these issues, but interest is increasing. In breast cancer, for example, should the recommendations for women who are found to have mammographically dense breasts on initial screening be the same as for the general population? These

Box1 | Colorectal cancer screening: financial implications

Annual cost estimate for universal colonoscopy at age 50

- Number of individuals in the United States who will turn 50 during a 12-month period: 3,000,000 (REF. 52)
- Cost of screening colonoscopy per person: US\$ 1,000 (REF. 58)
- Annual cost of universal population-based screening by colonoscopy for 50-year olds, excluding costs related to follow-up of abnormalities detected: US\$ 3,000,000,000
- Cost estimate in terms of dollars needed to save 1 year of life: US\$ 10,000–25,000 per year of life saved⁵³

women have an increased risk of breast cancer²⁷, which might imply the potential for increased benefit. Conversely, mammography might be less able to accurately identify small lesions in these women²⁴. Colorectal cancer provides another example in which we need more information to 'customize' screening recommendations on the basis of known risk factors of modest magnitude, such as polymorphisms in known tumour-suppressor genes²⁸ or high IGF1 levels²⁹. In the more extreme case of certain hereditary polyposis syndromes, the role for colorectal screening is limited because the risks are so high that most favour colectomy before adulthood³⁰.

Lack of sensitive serum markers. The identification of reliable serum markers for detecting curable cancers has been a long-standing research goal³¹. Some markers, such as carcinoembryonic antigen (CEA), have been found to be useful aids for physicians in determining the response to treatment, but lack the sensitivity and specificity that is required for screening. PSA is more useful for screening than CEA, but its optimum use still remains controversial. Ongoing research using genomic approaches to analyse gene expression in tumours, or using proteomic approaches in the analysis of serum, might identify more sensitive markers than those that are available at present. However, this might create dilemmas. A positive 'cancer test' in the absence of symptoms or a lesion that can be detected by imaging would present difficult decisions for patients and physicians.

Financial obstacles to screening
Colorectal cancer illustrates some of the serious financial implications of adopting a nationwide screening programme. Although it is uncertain which methods are most effective, screening for colorectal cancer is generally regarded as useful in reducing colon cancer incidence and mortality^{32–34}. But how much will it cost?

The data indicating that screening for colorectal cancer by sigmoidoscopy can save lives are convincing, but flexible sigmoidoscopy as a first-line screening tool has not gained acceptance. This is probably because a one-time flexible sigmoidoscopy after a positive faecal occult blood test is thought to miss a quarter of all advanced cancers; these are beyond the reach of the sigmoidoscope and do not have a distal polyp in association with the proximal cancer³⁵. Randomized studies of one-time colonoscopy are in progress, and data available at present strongly indicate that colonoscopy every 10 years or even once at age 50 years would result in a reduction in colorectal cancer mortality³². Other, non-invasive techniques, such as 'virtual colonoscopy', might replace endoscopic techniques, but they remain undervalued at present³⁶.

Even colonoscopy is far from perfect. Recent research has questioned the universality of a simple adenoma–carcinoma progression model of colorectal carcinoma. In particular, studies of hyperplastic polyps have indicated that pathways to colorectal cancer might be more varied than was previously thought³⁷. These findings could limit the effectiveness of screening and polypectomy as a method of reducing colorectal cancer mortality in individuals in whom stepwise carcinogenesis proceeds quickly.

Although colonoscopy still seems to be the best alternative, the financial costs would be enormous (BOX 1). In fact, the implementation of colonoscopy is not even practical at present, as there are not enough physicians performing colonoscopies. If the costs of colonoscopy could be substantially reduced, this method might become a viable option³⁴, but, at the moment, most societies will not be able to afford universal colonoscopy screening. Once-only population-based flexible sigmoidoscopy might be a practical alternative, even though it is acknowledged that it is not an ideal test. Cost-effectiveness analyses provide support for yearly re-hydrated faecal occult blood tests, combined with a sigmoidoscopy every 5 years from age 50 years to 85 years (REF. 33). A large

multicentre randomized trial of once-only flexible sigmoidoscopy at age 60 years is now underway in the UK and Italy. The first analysis of mortality data can be expected in 2004 (REF. 38). If this trial shows important benefits, single flexible sigmoidoscopy by nurse practitioners will deserve consideration as a practical choice for population-based colorectal cancer screening, particularly in view of the evidence that nurse practitioners are capable of performing sigmoidoscopy to the same performance level as gastroenterologists³⁹. Of course, those who can pay for the 'best' screening test might choose more aggressive or comprehensive screening options, but this is hardly a way to determine the best approach to population-based screening, which, by its very nature, must be funded from taxation.

Elementary anatomical issues are relevant to the practicality of screening: one reason for the success of Pap screening for cancer of the uterine cervix is that screen-detected lesions can often be dealt with conveniently in a practitioner's office without the need for expensive or dangerous interventions. A finding that lung cancer mortality could be reduced by repeated spiral CT scans of at-risk populations would be problematic, particularly if the effect on mortality were small, not only because of the cost of implementing a screening programme, but also because of the need to increase bronchoscopy and/or thoracic-surgery capacity to deal with the screen-detected lesions, many of which will be false positives⁴.

How to evaluate screening?

Evaluation of the benefits of a screening method is complex. The first data that become available during formal or informal attempts to assess the value of a screening modality relate to the number of occult cancers detected. Detection of occult cancers is necessary but not sufficient for a screening method to be useful. An obvious hazard, particularly in efforts to screen for neoplasms such as small-cell lung cancers that tend to metastasize early, is that screening will identify occult cancers, but subsequent to metastasis. Even an impressive detection rate, in the absence of documentation of improved survival, cannot be used to justify the introduction of a screening method into clinical practice. The current controversy regarding the value of mammography provides a clear example of difficulties that are related to statistical techniques used to evaluate screening methodology^{2,40}.

In most cancer screening trials, disease-specific mortality is measured. In clinical trials of treatment, purists prefer to measure overall

Box 2 | Evaluation of screening techniques

The argument for 'all-cause' mortality versus 'disease-specific' mortality⁴¹:

- Screening trials often measure 'disease-specific' mortality as the key outcome measure. This approach might be inadequate to fully reflect the impact of a screening test.
- Deaths caused, both directly and indirectly, by screening tests themselves might be incorrectly attributed to other causes. These deaths caused are often not accounted for as disease-related mortality.
- Deaths from cancer in the control group might be misattributed to other causes, or deaths in the screened group due to other causes are attributed to the screened cancer and are not accounted for as 'all cause'. This results in a 'sticky diagnosis' because the cancer diagnosis 'attracts' other diseases that are, in fact, the true cause of death.
- This indicates that disease-specific mortality might be a suboptimal end point for screening trials and that a reduction in disease-specific mortality cannot be cited as strong evidence of efficacy when the all-cause mortality is the same or higher in the screened group.
- When all-cause mortality is considered to be an end point, it might be increasingly difficult to identify the benefits of screening for late-onset cancers such as ovarian, prostate and colorectal cancer, especially in an ageing population.
- Recent data on the use of hormone-replacement therapy as a way of reducing mortality rates in post-menopausal women, and the use of tamoxifen to prevent breast cancer, have illustrated the problems with using measures other than all-cause mortality in evaluating an intervention that is designed to lower cancer mortality.

mortality, particularly when potentially dangerous treatments are involved. Recent data from Black and colleagues, summarized in BOX 2, indicate that it is also preferable to consider all-cause mortality as the measured end point in trials of screening. This opinion is based on the re-analysis of 12 published, randomized trials of cancer screening (including seven of mammography) in which seven of the studies had all-cause and disease-specific mortality rates that went in opposite directions, or differed significantly in magnitude⁴¹. Interestingly, the analysis of Black *et al.* confirms⁴¹ that the Edinburgh breast cancer screening trial⁴² had highly biased randomization, as the all-cause mortality in the control group was significantly greater than the breast cancer mortality in this group. This might relate, at least in part, to social class differences in the screened and observation groups.

It is likely that all-cause mortality is a less biased end point than cause-specific mortality. Therefore, when assessing the outcome of screening trials, it is important to remember that the total number of deaths in each arm of the study is ultimately more relevant to the success or failure of screening programmes than the number of any specific cause of death. This approach has been criticized by statisticians, radiologists and epidemiologists^{40,43,44}. The main argument put forward by these critics is that many of the differences between cause-specific and all-cause mortality that were noted by Black and colleagues could be due to chance, as deaths attributed to the cancer for which screening has been initiated will inevitably represent only a small fraction of the

total number of deaths in a screened population. The central point that Black and colleagues re-iterate in their response is that it is inherent in screening programmes that few will be helped, some will be harmed and most will be unaffected⁴⁵. Intemperate attacks⁴⁶ on those prepared to question the existing dogma^{2,47} indicate the entrenched nature of the views held, and indicate that these issues will not easily be resolved.

Unfortunately, the end points that provide the most rigorous answers are the most expensive and time-consuming to obtain, requiring at least years and possibly decades. The time and resources required are such that it is unrealistic to formally evaluate all proposed screening methods. Only those that show particular promise in preliminary studies and seem feasible for general application if they prove useful can be studied. These are difficult decisions, and it is a matter for debate whether, for example, trials of spiral CT imaging of smokers⁴ represent a wise use of resources⁴⁷.

Further challenges arise in areas of rapidly evolving technology that are related to screening. If serum proteomics or novel imaging methods show promise, how should it be determined when the method is optimized to a degree that would justify a significant trial? Advocates for the introduction of new screening methods are generally correct when they predict significant technical advances over the next decade — does this argue for waiting, rather than undertaking, a trial based on soon-to-be suboptimal instrumentation?

Overall, these caveats are not meant to give the impression that progress in the development of screening methods is impossible. On the contrary, we believe that refinement of screening methods now in use, though challenging, is necessary if population-based screening is to fill its potential as a method of cancer control. If current screening methods were an unqualified success, questions as to its effectiveness would not result in such scientific and public controversy⁴⁸.

Way forward

The public's view of screening is fairly straightforward: if a cancer is found early, then cure is more likely and therefore screening is a good thing. The first part of the clause is generally true, but the second part is less clear. Many recent publications do not make encouraging reading^{2,3}. Not only are there significant methodological problems with the interpretation of the results of trials, but also, as we have suggested, particular subgroups differ from the general population with respect to absolute cancer risk, mechanisms of carcinogenesis and the characteristics of their cancers. This means that clinical trials of screening protocols might be more informative if they stratify participants by biological and other markers of pre-existing risk. Results obtained in population-based 'all-risks' studies might not be translatable to individuals in specific risk groups and *vice versa*. A new look at the scientific rationale of screening studies is justified, and a renewed focus on primary prevention is warranted.

Advances in areas such as medical physics and serum proteomics are necessary but not sufficient to allow for significant improvements in the contribution of screening to cancer control. Also needed are biological and epidemiological information that will guide the application of new screening modalities in ways that will optimize reduction in cancer morbidity and mortality, as well as minimizing the number of unnecessary surgical interventions. In addition, attention must be given to the relationship between cancer screening and cancer prevention. It is imprecise to regard screening as a prevention strategy. Screening results in early detection, whereas successful prevention results in fewer invasive cancers and/or delayed carcinogenesis. Conventional screening must be combined with a treatment modality to be worthwhile.

Conventional models regard cancer as the target; in this context, the goal of screening is detection of macroscopic (but

small) cancers, and subsequently undertaking curative surgery. But there might be more potential for screening than the detection of cancers that are clinically occult. TABLE 1 contrasts the goals of screening populations for incident cancers, screening for risk of cancer and screening to identify individuals who stand to benefit from particular risk-reduction strategies.

As pointed out by Michael Sporn, it might be useful to consider the process of carcinogenesis as an alternative target⁴⁹. In this context, screening would be directed towards identifying those individuals who have a particular propensity towards rapid rates of carcinogenesis on the basis of unusual exposure to carcinogens, a high-risk hormonal profile, a specific genetic predisposition or lifestyle factors. Having identified, through screening, those individuals with a particular mechanism that predisposes them to carcinogenesis, appropriate prevention interventions tailored to the at-risk individual might be offered.

We are far from achieving this kind of intervention in oncology, but a useful precedent is provided by everyday practice in cardiology. Screening to reduce mortality from myocardial infarction is not based on assessing the coronary arteries in asymptomatic individuals. Rather, it is commonplace to screen populations for particular modifiable risk factors that predispose to coronary artery disease (such as hypertension) and then offer appropriate prevention strategies. So, the screening is primarily designed to identify those with risk factors for heart disease, and

to guide preventative interventions, rather than to identify those who already have occlusion of coronary arteries.

We speculate that the notion of screening populations to identify those who have the most to gain from specific risk-reduction strategies (as distinct from screening to detect early cancers) might become more common. A recent report⁵⁰ presents clinical criteria that identify individuals who benefit most from the use of tamoxifen as a breast cancer prevention strategy. It is possible that genetic or hormonal measurements could improve these predictions. In a sense, detection of *BRCA1* mutations represents a prototype of this kind of screening — a positive result indicates risk, rather than the presence of cancer, and has implications for prevention (in this case, prophylactic surgery) rather than for the treatment of cancers that are already present.

Notwithstanding the enormous challenges, efforts to use population screening to control cancer morbidity and mortality will continue as long as our success in treating advanced cancer remains limited. Some screening methods, such as Pap tests for cancer of the cervix, are clearly useful in reducing the number of individuals who come to medical attention with late-stage disease, and in reducing death rates⁵¹. Other screening methods, even those regarded in the older literature as obviously worthwhile — breast self-examination, for example — are being re-examined in the light of the notion that 'number of cancers detected' might not be the best end point. At present, the field is in flux: just as the usefulness of older screening techniques and the methods used to evaluate

their benefits are being questioned, basic research is providing new imaging methods and serum markers, some of which deserve clinical evaluation.

Michael N. Pollak and William D. Foulkes
are in the Programs of Cancer Prevention
and Cancer Genetics,
McGill University, Montreal,
Quebec, Canada H3T 1E2.
Correspondence to M. P.
e-mail: michael.pollak@mcgill.ca

doi:10.1038/nrc1042

Table 1 | Prevention and screening: distinct but related

	Screening for cancer	Screening for risk	Screening for potential to benefit from a prevention strategy
Goal	Find cancers that are surgically curable	Find people that have high or low risk	Identify people whose risk level is modifiable by a particular pharmacological or lifestyle intervention
Example	Mammography	Determining presence of germline <i>BRCA1/2</i> mutation	None shown so far; a representative hypothesis is that efficacy of SERMs in reducing post-menopausal breast cancer risk will be greatest in those women with high circulating oestradiol levels

At present, most screening procedures in oncology involve efforts to find incident asymptomatic cancers. Obviously, to be of benefit, this kind of screening must be combined with therapies, usually surgical, to remove the primary tumour. 'Screening' for genetic predisposition factors or for circulating hormone profiles associated with risk represents an effort to describe heterogeneity of risk within a population, rather than to identify those individuals with occult cancers. Finally, the concept of screening a population to identify those individuals who stand to benefit most from specific prevention strategies is at the interface between cancer screening research and cancer prevention research and deserves further study. The goal here is to identify subpopulations for whom particular prevention interventions would be most likely to be useful. Such information could result in more targeted application of prevention strategies, much as cardiologists direct antihypertensives not to everyone, but specifically to the subpopulation that, identified by blood pressure determination, is most likely to benefit. SERMs, selective oestrogen-receptor modulators.

- Baxter, N. Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? *CMAJ* **164**, 1837–1846 (2001).
- Olsen, O. & Gotzsche, P. C. Cochrane review on screening for breast cancer with mammography. *Lancet* **358**, 1340–1342 (2001).
- Woolf, S. H. The accuracy and effectiveness of routine population screening with mammography, prostate-specific antigen, and prenatal ultrasound: a review of published scientific evidence. *Int. J. Technol. Assess. Health Care* **17**, 275–304 (2001).
- Mulshine, J. L. Opinion: Screening for lung cancer: in pursuit of pre-metastatic disease. *Nature Rev. Cancer* **3**, 65–73 (2003).
- Petricoin, E. F. *et al.* Use of proteomics patterns in serum to identify ovarian cancer. *Lancet* **359**, 572–577 (2002).
- Nicholson, P. W. & Harland, S. J. Survival prospects after screen-detection of prostate cancer. *BJU Int.* **90**, 686–693 (2002).
- Neugut, A. I., Jacobson, J. S. & Rella, V. A. Prevalence and incidence of colorectal adenomas and cancer in asymptomatic patients. *Gastrointest. Endosc. Clin. N. Am.* **7**, 387–399 (1997).
- Neal, D. E. & Donovan, J. L. Prostate cancer: to screen or not to screen. *Lancet Oncol.* **1**, 17–24 (2000).
- Whitmore, W. F. Localized prostate cancer: management and detection issues. *Lancet* **343**, 1263–1267 (1994).
- Bok, R. A. & Small, E. J. Bloodborne biomolecular markers in prostate cancer development and progression. *Nature Rev. Cancer* **2**, 918–926 (2002).
- Lofters, A., Juffs, H. G., Pond, G. R. & Tannock, I. F. 'PSA-itis': knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer. *J. Urol.* **168**, 2516–2520 (2002).
- Tannock, I. F. Eradication of a disease: how we cured symptomless prostate cancer. *Lancet* **359**, 1341–1342 (2002).
- Pollak, M. Insulin-like growth factors and prostate cancer. *Epidemiol. Rev.* **23**, 59–66 (2001).
- Chan, J. M. *et al.* Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. *J. Natl Cancer Inst.* **94**, 1099–1106 (2002).
- Greller, L. D., Tobin, F. L. & Poste, G. Tumor heterogeneity and progression: conceptual foundations for modeling. *Invasion Metastasis* **16**, 177–208 (1996).
- Foulkes, W. D. *et al.* Primary node negative breast cancer in *BRCA1* mutation carriers has a poor outcome. *Ann. Oncol.* **11**, 307–313 (2000).
- Van de Vijver, M. J. *et al.* A gene-expression signature as a predictor of survival in breast cancer. *N. Engl. J. Med.* **347**, 1999–2009 (2002).
- Chappuis, P. O., Nethercot, V. & Foulkes, W. D. Clinicopathological characteristics of *BRCA1*- and *BRCA2*-related breast cancer. *Sem. Surg. Oncol.* **18**, 287–295 (2000).
- Porter, P. L. *et al.* Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. *J. Natl Cancer Inst.* **91**, 2002–2008 (1999).
- Breklemans, C. T. *et al.* Effectiveness of breast cancer surveillance in *BRCA1/2* gene mutation carriers and women with high familial risk. *J. Clin. Oncol.* **19**, 924–930 (2001).
- Tabar, L., Duffy, S. W., Vitak, B., Chen, H.-H. & Prevost, T. C. The natural history of breast carcinoma: what have we learned from screening? *Cancer* **86**, 449–462 (1999).
- Goffin, J., Chappuis, P. O., Wong, N. & Foulkes, W. D. Re: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. *J. Natl Cancer Inst.* **93**, 1754–1755 (2001).

23. Stoutjesdijk, M. J. *et al.* Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. *J. Natl Cancer Inst.* **93**, 1095–1102 (2001).
24. Warner, E. *et al.* Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. *J. Clin. Oncol.* **19**, 3524–3531 (2001).
25. Meijers-Heijboer, H. *et al.* Breast cancer after prophylactic bilateral mastectomy in women with a *BRCA1* or *BRCA2* mutation. *N. Engl. J. Med.* **345**, 159–164 (2001).
26. Julian-Reynier, C. M. *et al.* Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. *Cancer* **92**, 959–968 (2001).
27. Boyd, N., Lockwood, G., Byng, J., Titchler, D. & Yaffe, M. Mammographic densities and breast cancer risk. *Cancer Epidemiol. Biomark. Prev.* **7**, 1133–1144 (1998).
28. Laken, S. J. *et al.* Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. *Nature Genet.* **17**, 79–83 (1997).
29. Ma, J. *et al.* Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. *J. Natl Cancer Inst.* **91**, 620–625 (1999).
30. Giardiello, F. M., Brensinger, J. D. & Petersen, G. M. AGA technical review on hereditary colorectal cancer and genetic testing. *Gastroenterology* **121**, 198–213 (2001).
31. Sidransky, D. Emerging molecular markers of cancer. *Nature Rev. Cancer* **2**, 210–219 (2002).
32. Anderson, W. F. *et al.* Colorectal cancer screening for persons at average risk. *J. Natl Cancer Inst.* **94**, 1126–1133 (2002).
33. Frazier, A. L., Colditz, G. A., Fuchs, C. A. & Kuntz, K. M. Cost-effectiveness of screening for colorectal cancer in the general population. *JAMA* **284**, 1954–1961 (2000).
34. Budenholzer, B. Cost-effectiveness of colorectal cancer screening. *JAMA* **285**, 407 (2001).
35. Lieberman, D. A. & Weiss, D. G. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. *N. Engl. J. Med.* **345**, 555–560 (2001).
36. Pineau, B. C. *et al.* Validation of virtual colonoscopy in the detection of colorectal polyps and masses: rationale for proper study design. *Int. J. Gastrointest. Cancer* **30**, 133–140 (2001).
37. Jass, J. R., Whitehall, V. L., Young, J. & Leggett, B. A. Emerging concepts in colorectal neoplasia. *Gastroenterology* **123**, 862–876 (2002).
38. Atkin, W. S. *et al.* Design of a multicentre randomised trial to evaluate flexible sigmoidoscopy in colorectal cancer screening. *J. Med. Screen.* **8**, 137–144 (2001).
39. Schoenfeld, P. *et al.* Accuracy of polyp detection by gastroenterologists and nurse endoscopists during flexible sigmoidoscopy: a randomized trial. *Gastroenterology* **117**, 312–318 (1999).
40. Kopans, D. B. The most recent breast cancer screening controversy about whether mammographic screening benefits women at any age: nonsense and nonsense. *Am. J. Roentgenol.* **180**, 21–26 (2003).
41. Black, W. C., Haggstrom, D. A. & Welch, G. All-cause mortality in randomized trials of cancer screening. *J. Natl Cancer Inst.* **94**, 167–173 (2002).
42. Alexander, F. E. *et al.* 14 years of follow-up from the Edinburgh randomized trial of breast-cancer screening. *Lancet* **353**, 1903–1908 (1999).
43. Church, T. R., Ederer, F. & Mandel, J. S. Re: All-cause mortality in randomized trials of cancer screening. *J. Natl Cancer Inst.* **94**, 861 (2002).
44. Gail, M. H. & Katki, H. A. Re: All-cause mortality in randomized trials of cancer screening. *J. Natl Cancer Inst.* **94**, 862 (2002).
45. Black, W. C., Haggstrom, D. A. & Welch, H. G. Re: All-cause mortality in randomized trials of cancer screening. *J. Natl Cancer Inst.* **94**, 865–866 (2002).
46. Rogers, L. F. Screening mammography: target of opportunity for the media. *Am. J. Roentgenol.* **180**, 1 (2003).
47. Mahadevia, P. J. *et al.* Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. *JAMA* **289**, 313–322 (2003).
48. Kolata, G. Breast cancer: mammography finds more tumors. Then the debate begins. *New York Times* (9 Apr 2002).
49. Sporn, M. D. & Suh, N. Chemoprevention: an essential approach to controlling cancer. *Nature Rev. Cancer* **2**, 537–543 (2002).
50. Veronesi, U. *et al.* Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. *J. Natl Cancer Inst.* **95**, 160–165 (2003).
51. Franco, E. L., Duarte-Franco, E. & Ferenczy, A. Cervical cancer: epidemiology, prevention and the role of HPV infection. *CMAJ* **164**, 1017–1025 (2001).
52. US Bureau of Census. An Aging World: 2001 [online], (cited 24 Feb 2003), <<http://www.census.gov/prod/2001pubs/p95-01-1.pdf>> (2001).
53. Pignone, M., Saha, S., Hoerger, T. & Mandelblatt, J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. *Ann. Intern. Med.* **137**, 96–104 (2002).
54. Greenwald, P. *et al.* Estimated effect of breast self-examination and routine physician examinations on breast cancer mortality. *N. Engl. J. Med.* **299**, 271–273 (1978).
55. Huguley, C. M. & Brown, R. L. The value of breast self-examination. *Cancer* **47**, 989–995 (1981).
56. Newcomb, P. A. *et al.* Breast self-examination in relation to the occurrence of advanced breast cancer. *J. Natl Cancer Inst.* **83**, 260–265 (1991).
57. Thomas, D. B. *et al.* Randomized trial of breast examination in Shanghai: final results. *J. Natl Cancer Inst.* **94**, 1445–1457 (2002).
58. Smith, R. A., Cokkinides, V. & Eyre, H. J. American Cancer Society guidelines for the early detection of cancer, 2003. *CA Cancer J. Clin.* **53**, 27–43 (2003).

Acknowledgements

The authors would like to thank R. Narasimhadevara for her contribution to this review. W.D.F. is a Principal Investigator of the Canadian Genetic Diseases Network. M.N.P. holds the Alexander Goldfarb Research Chair in Medical Oncology at McGill University.

Online links

DATABASES

The following terms in this article are linked online to: **Cancer.gov**: http://www.cancer.gov/cancer_information/breast_cancer | colon cancer | ovarian cancer | prostate cancer | small-cell lung cancer
LocusLink: <http://www.ncbi.nih.gov/LocusLink/BRCA1> | [BRCA2](http://www.ncbi.nih.gov/LocusLink/BRCA2) | p53 | PSA

FURTHER INFORMATION

McGill Program in Cancer Genetics:

www.mcgill.ca/cancergenetics

McGill Program in Cancer Prevention:

www.mcgill.ca/cancerprev

Access to this interactive links box is free online.

OPINION

Improving the evaluation of new cancer treatments: challenges and opportunities

Mace L. Rothenberg, David P. Carbone and David H. Johnson

There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?

In the dynamic new era of clinical cancer research, it is estimated that there are more 350 new agents that are in clinical development at present for cancer or cancer-related indications¹. This is more than ten times the number of agents we had 15 years ago. Yet, along with this unprecedented opportunity, a sense of uncertainty and frustration permeates the fields of cancer treatment research and drug development. The apparently straightforward task of designing clinical trials that can clearly establish the beneficial impact of a new agent on a patient with cancer has become

increasingly difficult. The problem lies in the fact that many of the new classes of agents are predicted to work only in small subpopulations of patients, affect tumours in an unconventional fashion and interact with other classical and novel agents in ways that we cannot yet predict. How can we resolve this clinical paradox and take full advantage of the opportunities for real progress that lie before us?

The price of success

In the 1990s, there was a surge in the development and approval of new drugs for oncological indications. Thirty-six new agents were approved for the treatment of cancer and cancer-related indications in that decade — more than in the preceding 40 years (FIG. 1; and see **FDA approval statistics** in online links box). Similarly, the number of claims approved by the Food and Drug Administration (FDA) for the treatment of cancer indications during the 1990s exceeded the number granted during the preceding 40 years (FIG. 2; and see **FDA approval statistics** in online links box). Identification of exploitable molecular targets,